START Center for Cancer Research, Baptist Health South Florida expand patient access to early-phase clinical trials

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more difficult in recent years?

May 29, 2026

Vol.52 No.21

By Paul Goldberg and Claire Marie Porter

Clinical

When CAM is added to standard therapies, survival rates drop, observational study finds

As complementary and alternative medicines continue to gain acceptance beyond the margins of cancer treatment, results from a recent study from Yale School of Medicine published in JAMA Network Open suggests that some patients using CAM with their mainstream therapy may, in fact, be substituting alternative medicine for allopathinc interventions.

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

May 29, 2026

Vol.52 No.21

In Brief

Dario C. Altieri joins Sidney Kimmel Jefferson as professor

Dario C. Altieri has joined the faculty of Sidney Kimmel Medical College, effective Jan. 1, 2027, following completion of his leadership tenure at The Wistar Institute, Thomas Jefferson University has announced.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.

May 22, 2026

Vol.52 No.20

START Center for Cancer Research, Baptist Health South Florida expand patient access to early-phase clinical trials

YOU MAY BE INTERESTED IN

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

When CAM is added to standard therapies, survival rates drop, observational study finds

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

Dario C. Altieri joins Sidney Kimmel Jefferson as professor

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Renew today!

Subscriber content

Never miss an issue!

Login